William Blair Estimates Alector's Q1 Earnings (NASDAQ:ALEC)

Alector, Inc. (NASDAQ:ALEC - Free Report) - Investment analysts at William Blair reduced their Q1 2025 earnings per share (EPS) estimates for shares of Alector in a note issued to investors on Thursday, February 27th. William Blair analyst M. Minter now expects that the company will earn ($0.53) per share for the quarter, down from their prior forecast of ($0.51). The consensus estimate for Alector's current full-year earnings is ($1.88) per share. William Blair also issued estimates for Alector's Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.14) EPS and FY2026 earnings at ($2.14) EPS.

Alector (NASDAQ:ALEC - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.59. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The company had revenue of $54.24 million during the quarter, compared to analysts' expectations of $20.41 million.

A number of other analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Alector in a research note on Tuesday, November 26th. Stifel Nicolaus downgraded Alector from a "buy" rating to a "hold" rating and set a $4.00 target price for the company. in a research report on Monday, December 16th. HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Alector in a research report on Thursday, February 27th. Morgan Stanley lowered Alector from an "equal weight" rating to an "underweight" rating and cut their price objective for the company from $10.00 to $3.00 in a report on Tuesday, November 26th. Finally, Mizuho cut Alector from an "outperform" rating to a "neutral" rating and decreased their target price for the company from $9.00 to $2.50 in a research note on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $3.75.

Alector Trading Up 6.5 %

ALEC traded up $0.10 on Monday, reaching $1.55. The company had a trading volume of 650,084 shares, compared to its average volume of 716,171. The company has a market capitalization of $153.58 million, a P/E ratio of -0.91 and a beta of 0.61. The company has a fifty day moving average of $1.75 and a 200-day moving average of $3.43. Alector has a one year low of $1.30 and a one year high of $7.10.

Hedge Funds Weigh In On Alector

A number of hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new stake in Alector during the fourth quarter valued at about $25,000. Tema Etfs LLC acquired a new stake in shares of Alector during the fourth quarter valued at approximately $27,000. Tower Research Capital LLC TRC lifted its position in shares of Alector by 71.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company's stock valued at $28,000 after acquiring an additional 6,096 shares in the last quarter. Point72 DIFC Ltd acquired a new position in Alector in the 3rd quarter worth approximately $29,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Alector during the 3rd quarter worth approximately $40,000. 85.83% of the stock is currently owned by institutional investors and hedge funds.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.